3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
39
Squamous Cell Carcinoma of Head and Neck
20
Lung Neoplasms
20
Oropharyngeal Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Urinary Bladder Neoplasms
7
Uterine Cervical Neoplasms
6
Endometrial Neoplasms
6
Carcinoma
6
Pancreatic Neoplasms
5
Mouth Neoplasms
5
Colorectal Neoplasms
5
Cholangiocarcinoma
5
Biliary Tract Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Nasopharyngeal Carcinoma
4
Laryngeal Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Squamous Cell
4
Mesothelioma, Malignant
3
Lymphoid Interstitial Pneumonia
3
Hypopharyngeal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Triple Negative Breast Neoplasms
2
Tongue Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Salivary Gland Neoplasms
2
Rectal Neoplasms
2
Interventions
Carboplatin
2
repotrectinib
1
pembrolizumab
1
durvalumab
1
Pemetrexed
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Neoplasms
×
Cisplatin
×
30 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled